Ascletis Pharma, Inc. Financials

Market Capitalization HK$14.50 Billion as of Jan. 1, 2026

Valuations Metrics as of Jan. 3, 2026

Trailing PE	-38.34
Forward PE	-41.14
Price to Sales TTM	HK$4807.25
Price to Book MRQ	HK$5.34
Enterprise to Revenue	3935.93
Enterprise to EBITDA	-22.79

Financial Reports as of Jun. 30, 2018

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2018-06-30
Profit Margin	57.29%
Operating Margin	-17609.62%
Return on Assets TTM	-12.32%
Return on Equity TTM	-12.78%

Income Statement

Revenue TTM	HK$2,628,720
Revenue per Share TTM	HK$0.00
Quarterly Revenue Growth	25.46%
Gross Profit TTM	HK$951,854
EBITDA	HK$-453,925,821
Net Income to Common TTM	HK$-287,523,547
Diluted EPS TTM	HK$-0.29
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	HK$2,002,603,745
Total Cash per Share MRQ	HK$1.87
Total Debt MRQ	HK$
Total Debt to Equity MRQ	0.23
Current Ratio MRQ	14.57
Book Value per Share MRQ	HK$2.16

Cash Flow

Operating Cash Flow TTM	HK$-345,997,007
Levered Free Cash Flow TTM	HK$-222,405,874

1672 Stock Info as of Jan. 3, 2026

Stock Statistics

Shares Outstanding	962,846,285
Float Shares	346,151,382
Avg 10 Volume	2,505,385
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	69.75%
% Held by Institutions	3.25%

Stock Price Summary

Beta	0.55
Fifty Two Week Low	HK$2.82
Fifty Two Week High	HK$18.75
Fifty Two Week Change	70.14%
Day 50 MA	HK$12.35
Day 200 MA	HK$10.29

Dividends and Splits

Forward Annual Dividend Rate	HK$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	HK$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date